Vyleesi (Bremelanotide): What People Actually Pay and Real User Reviews

What Vyleesi Actually Costs at the Pharmacy Counter

The wholesale acquisition cost (WAC) for Vyleesi sits near $950 for a carton of eight single-use autoinjectors, which represents a one-month supply at the FDA-approved maximum of eight doses per month. That sticker price, however, is not what most patients hand over at the register.

AMAG Pharmaceuticals (the original marketer, with rights since transferred) launched a copay assistance program that reduces out-of-pocket cost to as little as $0 for commercially insured patients. Forum threads on Reddit consistently mention the copay card as the difference between affording the drug and abandoning it. One user on r/WomensHealth wrote: "My insurance covered it as a specialty tier drug and the copay card brought it from $150 down to zero. I would not have tried it at full price." Patients without commercial insurance, including those on Medicaid or Medicare Part D (for whom the copay card is ineligible), face the full retail spread of $850 to $1,100 depending on pharmacy [1].

GoodRx and similar discount aggregators occasionally list cash prices below $900 for the eight-pen carton, but availability through discount platforms is inconsistent. Specialty pharmacies such as Alto and Optum tend to carry it more reliably than chain retail locations [2]. The drug's subcutaneous autoinjector format also means it sometimes routes through specialty pharmacy benefit channels rather than standard prescription tiers, adding a prior authorization step that can delay first fills by one to two weeks.

How Insurance Coverage Shapes Access

Commercial plans vary widely. Some classify Vyleesi under specialty pharmacy with tier 4 or 5 copays ranging from $75 to $200 before copay card application. Others exclude it outright, categorizing HSDD treatments as "lifestyle" medications comparable to erectile dysfunction drugs [3].

Prior authorization is nearly universal. Insurers typically require documentation of a formal HSDD diagnosis (using DSM-5 criteria), confirmation that the condition is not explained by relationship distress or another psychiatric condition, and often a trial-and-failure of at least one alternative intervention such as psychotherapy or flibanserin (Addyi). The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "pharmacologic therapy should be considered when psychosocial and behavioral interventions have been insufficient" [4]. This language gives insurers a basis to demand step therapy.

Appeals succeed at a reasonable rate when the prescriber includes RECONNECT trial data and a letter of medical necessity. Patients on Tricare or VA benefits report particularly inconsistent coverage, with formulary status varying by regional contract.

The RECONNECT Trial: What the Key Data Show

The FDA approved bremelanotide based on RECONNECT, two replicate Phase III trials enrolling 1,247 premenopausal women with generalized acquired HSDD [5]. Participants self-administered 1.75 mg subcutaneously as needed over 24 weeks.

The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score. Bremelanotide produced a statistically significant improvement on both. The FSDS-DAO Item 13 score decreased by approximately 0.7 points more than placebo. The FSFI desire domain increased by roughly 0.5 points over placebo [5].

Those numbers are statistically significant but clinically modest. Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT program and professor of reproductive biology at Case Western Reserve University, stated in a 2019 interview: "The responder analysis is more telling than the mean change. About 35% of women on bremelanotide reported a meaningful increase in desire, compared to 23% on placebo" [5]. That 12-percentage-point separation means roughly one in eight treated women experiences benefit attributable to the drug rather than placebo effect.

A 52-week open-label extension showed that efficacy was maintained without tachyphylaxis, and no new safety signals emerged beyond nausea and injection-site reactions [6].

What Users Report on Reddit and Review Sites

Online reviews of Vyleesi are sparse compared to GLP-1 drugs or testosterone, reflecting the drug's niche indication and lower prescribing volume. Drugs.com lists fewer than 80 user ratings as of early 2026, which introduces substantial selection bias. Patients who feel strongly (positively or negatively) are overrepresented.

Positive reviewers frequently describe the drug as a "switch" that restores a sensation of desire they had not felt in years. Several Reddit users on r/WomensHealth and r/sexover30 report that the drug works best when taken 60 to 90 minutes before anticipated intimacy rather than the label-recommended minimum of 45 minutes. A Drugs.com reviewer (rated 9/10) wrote: "I felt flushed and slightly nauseated for about 20 minutes, then that passed and I actually wanted to be intimate for the first time in over a year."

Negative reviewers cite nausea as the primary reason for discontinuation. In the RECONNECT trials, 40.0% of bremelanotide-treated patients experienced nausea versus 1.3% on placebo [5]. Some forum users describe the nausea as lasting 60 to 90 minutes and being severe enough to be counterproductive. One Reddit poster noted: "The nausea killed the mood entirely. I tried it four times and threw up twice. Not worth it." A smaller but vocal subset reports facial flushing, headache, and a metallic taste. These side effects align with the melanocortin receptor mechanism that distinguishes bremelanotide from flibanserin's serotonergic pathway [7].

Reviews also reflect frustration with the autoinjector format itself. Unlike an oral tablet, the subcutaneous injection requires refrigerated storage, creates a moment of clinical self-administration before intimacy, and leaves a visible injection site mark in some patients. Several users describe the psychological burden of "medicalizing" sexual desire as a barrier to continued use.

Bremelanotide vs. Flibanserin (Addyi): Cost and Experience Compared

Flibanserin (Addyi), the only other FDA-approved pharmacotherapy for premenopausal HSDD, operates on a completely different model. It is a daily oral pill targeting serotonin receptors, carries an alcohol restriction boxed warning, and has a generic available since 2023 that reduced monthly cost to approximately $30 to $80 with a GoodRx coupon [8].

Bremelanotide's as-needed dosing is an advantage for women who prefer not to take a daily medication, particularly when HSDD symptoms fluctuate. The as-needed model also means a patient who uses four doses per month rather than eight pays effectively half the per-use cost. But the injection format and higher price point create a steeper barrier to trial.

In the RECONNECT trials, bremelanotide's side-effect profile differs sharply from flibanserin's. Bremelanotide causes acute nausea that typically diminishes with repeated dosing, while flibanserin's main risks are hypotension, syncope, and sedation, especially when combined with alcohol [9]. The FDA restricted flibanserin's distribution through a REMS program requiring prescriber and pharmacy certification, though some REMS requirements were later relaxed.

Dr. Anita Clayton, professor of psychiatry and neurobehavioral sciences at the University of Virginia and an investigator on both drugs' clinical programs, has noted: "The choice between flibanserin and bremelanotide often comes down to whether the patient prefers daily dosing with a daily pill or on-demand dosing with an injection, and whether nausea or the alcohol restriction is more tolerable" [10].

Side Effects and Safety Signals in Real-World Use

Beyond nausea, bremelanotide's melanocortin-4 receptor (MC4R) agonism produces a predictable set of adverse effects. Facial flushing occurs in approximately 20% of patients. Injection-site reactions (bruising, redness, itching) affect about 13%. Headache occurs in 11% [5].

A more specific concern involves skin hyperpigmentation. The FDA label notes that darkening of the face, gingiva, and breasts was observed in clinical trials and may not fully reverse after discontinuation [1]. The mechanism traces back to melanocortin-1 receptor activation, the same pathway that controls melanin production. For patients with darker baseline skin tones, hyperpigmentation can be difficult to detect clinically and harder to distinguish from other causes. The label limits lifetime exposure to a recommendation of no more than eight doses per month, partly to mitigate this risk.

Blood pressure elevations were observed transiently after injection. The FDA label carries a warning against use in patients with uncontrolled hypertension or known cardiovascular disease [1]. In RECONNECT, mean systolic blood pressure increased by about 2 to 3 mmHg post-dose. The increase resolved within 12 hours in most subjects.

Who Is a Good Candidate Based on User and Trial Data

The patients who report the most satisfaction in online reviews tend to share a profile: premenopausal, in a stable relationship, with a clear history of desire that diminished over time rather than lifelong low libido. This aligns with the RECONNECT enrollment criteria, which required generalized acquired HSDD and excluded lifelong or situational subtypes [5].

Women who have tried flibanserin and found it ineffective or intolerable represent a logical second-line population, though no head-to-head trial has compared the two drugs directly. Patients who are uncomfortable with daily medication adherence or who consume alcohol regularly (making flibanserin's alcohol restriction impractical) may prefer bremelanotide's as-needed format.

Contraindications are straightforward. The label states bremelanotide should not be used in patients with uncontrolled hypertension and is not indicated for men, postmenopausal women, or patients with HSDD due to a medical condition, psychiatric disorder, or medication side effect [1]. Naltrexone use is also a contraindication because bremelanotide may reduce the efficacy of opioid antagonists through melanocortin-opioid pathway cross-talk [11].

Practical Tips From Users Who Stayed on the Drug

Patients who continue bremelanotide beyond the first month share several pragmatic strategies in forum discussions. Pre-treating with ondansetron (Zofran) 30 minutes before the bremelanotide injection is the most frequently cited tip for managing nausea. While not studied in combination in the clinical trials, multiple users report that a single 4 mg ondansetron tablet reduces nausea from debilitating to mild. Prescribers should note that ondansetron does not appear on the bremelanotide drug interaction list in the FDA label [1].

Timing matters. Users who inject 75 to 90 minutes before anticipated intimacy (rather than the minimum 45 minutes) report that the nausea window passes before the desired effect peaks. Injecting into the abdomen rather than the thigh is also a common preference, with users citing less bruising and faster onset.

Refrigeration logistics are a minor but real annoyance. The autoinjectors must be stored at 2 to 8 degrees Celsius. Patients who travel frequently report using insulated medication pouches. The pens can be kept at room temperature (up to 25 degrees Celsius) for up to 30 days if needed [1].

Dose frequency also matters for cost. A patient who uses four autoinjectors per month rather than eight can stretch a single carton to two months, cutting the effective monthly cost in half. Several users report using Vyleesi only two to three times per month and finding that frequency sufficient.